Loading clinical trials...
Loading clinical trials...
A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Subjects With Pyruvate Kinase Deficiency
Conditions
Interventions
RP-L301
Locations
3
United States
Stanford University
Palo Alto, California, United States
Hospital Infantil Universitario Niño Jesús
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Start Date
August 1, 2024
Primary Completion Date
November 1, 2026
Completion Date
January 1, 2029
Last Updated
May 22, 2024
NCT04964323
NCT03548220
NCT03559699
Lead Sponsor
Rocket Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions